Skip to the content
Close
  • Funds
    Show sub menu
    • Products
    • Fund NAVs
    • Regulatory
  • Portfolio Managers
    Show sub menu
    • Canso Investment Counsel Ltd.
    • Fulcra Asset Management
    • Slater Asset Management
    • Triasima Portfolio Management
    • Patient Capital Management
    • Crusader Asset Management
    • SEAMARK Asset Management
    • Pembroke Management Ltd.
  • Insights
  • About
    Show sub menu
    • About Us
    • Our Team
    • Awards
    • Careers
  • en
  • fr
Follow us on
  • LinkedIn
Lysander Funds Ltd. Lysander Funds Ltd. Lysander Funds Ltd.
  • Funds
    • Products
    • Fund NAVs
    • Regulatory
  • Portfolio Managers
    • Canso Investment Counsel Ltd.
    • Fulcra Asset Management
    • Slater Asset Management
    • Triasima Portfolio Management
    • Patient Capital Management
    • Crusader Asset Management
    • SEAMARK Asset Management
    • Pembroke Management Ltd.
  • Insights
  • About
    • About Us
    • Our Team
    • Awards
    • Careers
  • en
  • fr
Search Menu
Close

Lysander-Patient Capital Equity Fund – Series A

  • Fund Code: LYZ905A
  • Portfolio Manager: Patient Capital Management Inc.
  • As of: March 31, 2025
  • Asset Class: Equity
  • CIFSC Category: Global Equity
  • Benchmark: S&P/TSX Composite Total Return Index1
Lysander Funds Ltd.

Investment Focus

A global equity fund that invests in a diversified portfolio consisting primarily of global equity securities.

Risk Rating

Low
Low-to-Medium
Medium
Medium-to-High
High

Why Invest in this Fund?

Established in 2000, Patient Capital Management is an independent firm with a highly disciplined and focused investment strategy anchored in Absolute Value.

The sole purpose of Patient Capital Management’s investment strategy is to preserve and grow the wealth of investors through the implementation of a long-term investment strategy focusing on the purchase of securities of high-quality businesses at a substantial discount to their intrinsic value.

When fully invested the portfolio will hold securities of approximately twenty to twenty-five issuers to maximize the return potential of each security selection.

Fund Facts

Inception Date December 30, 2014
Currency CAD
Fund AUM $15.6 Million
NAVPU $13.06
Management Fee 1.80%
MER as of December 31, 2024 2.13%
Minimum Initial Investment $500
Minimum Subsequent Investment $100
Liquidity Daily
RSP Eligible Yes

Compound Returns – Series A

1 Month 3 Months YTD 1 Year 3 Year
(Annualized)
5 Year
(Annualized)
10 Year
(Annualized)
Since Inception
(Annualized)
-0.9% 0.2% 0.2% 2.8% 3.4% 11.4% 4.8% 4.9%

Calendar Year Returns – Series A

Lysander Funds Limited
Lysander-Patient Capital Equity Fund – Series A

Top 10 Holdings

Security % of Fund
Canada T-Bill Due June 4/25 36.2%
BCE Inc. 7.1%
Bank of Nova Scotia 6.6%
Cdn. Utilities Ltd. 6.5%
Verizon Communications Inc. 5.8%
Toronto Dominion Bank 5.5%
Bank of Montreal 5.3%
Firm Capital Property Trust 5.3%
Honda Motor Co. Ltd. ADR 5.3%
Canadian Imperial Bank of Commerce 4.5%
Total 88.1%

Portfolio Characteristics

Number of Securities 16
Dividend Yield (%) 5.0%

Geographic Breakdown

Canada 88.9%
USA 5.8%
Other 5.3%

Distributions

  • Distribution Frequency: Quarterly
  • Most Recent Distribution per Unit: $0.0894
  • 12-Month Trailing Distribution Yield: 3.4%
  • Next Record Date: June 19, 2025
  • Next Distribution Date: June 20, 2025
Distributions ($)/Unit2 YTD* 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Total Distributions 0.0894 0.4576 0.5005 0.1361 2.7860 0.0619 0.6172 0.0456 0.0373 0.0216 –
Interest – 0.0638 0.1083 0.0301 – – – – – – –
Dividends – 0.3346 0.2551 0.1060 0.2033 0.0619 0.1721 0.0382 0.0373 0.0216 –
Capital Gains – 0.0645 0.1427 – 2.5827 – 0.4451 0.0074 – – –
Withholding Tax – (0.0054) (0.0055) – – – – – – – –
*The final tax character will be determined based on the Fund’s tax year end information.
Lysander Funds Limited
Lysander-Patient Capital Equity Fund – Series A

Lysander Funds Limited is the investment fund manager of Lysander-Patient Capital Equity Fund (the “Fund”). This document is not an invitation to invest in the Fund and does not constitute a public offering of sale. Purchases in the Fund can only be made through an Investment Professional on the terms in the Fund’s offering document by eligible investors. Each purchaser of units in a fund may have statutory or contractual right of action. Please read the prospectus before investing. Commissions, trailing commissions, management fees and expenses all may be associated with investment funds.

The indicated rates of return are historical annual compounded total returns including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Investment funds are not guaranteed or insured, their values change frequently and past performance may not be repeated.

1TSX © Copyright 2025 TSX Inc. All Rights Reserved.

2Distributions are based on the actual number of units outstanding at the relevant time. Distributions are paid in cash or reinvested in additional units. If the series’ net income/capital gains is less than the amounts distributed in the year, the distribution will include a return of capital. In these circumstances, if an investor elects to receive their distributions in cash and not reinvest distributions, it is expected that the value of their investment will decline over time. Distributions are not an indication of performance, rate of return or yield.

On November 1, 2021, the portfolio manager of the fund changed from 18 Asset Management Inc. to Patient Capital Management Inc. and the investment objective of the fund no longer had a Canadian equity securities focus. These changes could have affected the performance of the fund had these changes been in effect throughout the performance measurement period.

Effective January 1, 2020, the management fee for Series A changed from 2.00% to 1.80% and Series F changed from 1.00% to 0.80%. This change could have affected the performance of the Fund had this change been in effect throughout the performance measurement period.

®Lysander Funds is a registered trademark of Lysander Funds Limited.

Lysander Funds Ltd., 3080 Yonge St., Suite 4000, Toronto, ON, M4N 3N1
Toll Free: (877) 308-6979 Website: www.lysanderfunds.com
Lysander Funds Limited

Looking for something?
We’re here to help.

Get in Touch
  • About
  • About Us
  • Our Team
  • Awards
  • Careers
  • Funds
  • Products
  • Fund NAVs
  • Regulatory
  • Portfolio Managers
  • Insights
  • Contact
Follow us on
  • LinkedIn

© 2025 Lysander Funds Ltd.

  • Legal and Terms of Use
  • Privacy Policy

Your Cookie Settings


We have updated our Privacy Policy effective October 2021. We encourage you to review it carefully.

We use cookies to improve your experience. By continuing to use this website, or other online services, you agree to the use of cookies and consent to the practices described in our Privacy Policy and Terms of Use.